A failed trial for a heart drug casts shadow over rivals developing similar therapies

MarketWatch · November 9, 2026, 13:54 UTC

Topics: clinical trial failure drug development pharmaceutical industry

Read the full article at MarketWatch

Part of the story Novartis to Halt Development of Ionis-Derived Heart Disease Therapy Following Clinical Trial Failure (2 articles)

More World news

Broadcom Shares Rise Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 19:47 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 Motley Fool · November 12, 2026, 19:48 UTC
Team, Inc. (TISI) Reports Q3 2026 Results Amid Turnaround Deferrals and Geopolitical Disruptions Motley Fool · November 12, 2026, 19:44 UTC
Berkshire Hathaway Stock Reaches Record Levels Amid CEO Greg Abel's Leadership Motley Fool · November 12, 2026, 19:45 UTC
Data I/O Reports Q3 2026 Results Amid V-TEK Acquisition and Automotive Softness Motley Fool · November 12, 2026, 19:45 UTC
Google Unveils Gemini 4 Hydrogen AI Model Optimized for Coding Efficiency Seeking Alpha · November 12, 2026, 19:44 UTC
CMS Announces Final Valuations and Reimbursement Rates for New ESD CPT Codes PR Newswire · November 12, 2026, 19:43 UTC
IRS Announces 2027 Retirement Contribution Limits and Social Security COLA Increase Motley Fool · November 12, 2026, 19:37 UTC
Yesway Reaffirms 2026 EBITDA Guidance and Outlines Texas Allsup’s Conversion Timeline Seeking Alpha · November 12, 2026, 19:40 UTC
Boost Run Reports 496% Year-Over-Year Revenue Growth in Q3 2026 Seeking Alpha · November 12, 2026, 19:40 UTC